Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAT + calcifediol
- Development stage
- Preclinical
- Lead developer
- OPKO Health
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves BAT (best available therapy) and calcifediol, a vitamin D3 analog. Calcifediol is used to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. It works by helping the body absorb calcium and regulating parathyroid hormone levels. The combination is explored in clinical settings for conditions like COVID-19, where the best available therapy is combined with calcifediol to enhance treatment outcomes.
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on BAT + calcifediol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAT + calcifediol.